Barclays
KYTX icon

Barclays’s Kyverna Therapeutics KYTX Stock Holding History

Barclays’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
117,844
-18,531
-14% -$165K ﹤0.01% 2764
2026
Q1 		$1.18M Sell
136,375
-28,293
-17% -$236K ﹤0.01% 2657
2025
Q4 		$1.55M Buy
164,668
+88,477
+116% +$657K ﹤0.01% 3111
2025
Q3 		$457K Buy
76,191
+25,797
+51% +$103K ﹤0.01% 3864
2025
Q2 		$155K Sell
50,394
-30,996
-38% -$76.7K ﹤0.01% 4402
2025
Q1 		$157K Sell
81,390
-8,196
-9% -$24.2K ﹤0.01% 4174
2024
Q4 		$335K Buy
89,586
+19,419
+28% +$93K ﹤0.01% 4060
2024
Q3 		$343K Buy
70,167
+12,418
+22% +$95.7K ﹤0.01% 4002
2024
Q2 		$433K Buy
57,749
+14,655
+34% +$224K ﹤0.01% 3125
2024
Q1 		$1.07M Buy
+43,094
New +$1.2M ﹤0.01% 3068

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Barclays's KYTX Position: Q2 2026 in Review

Barclays reduced its Kyverna Therapeutics (KYTX) stake by 14% in Q2 2026, selling an estimated $165K and leaving 117,844 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

Barclays first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.55M in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Barclays held 117,844 shares of Kyverna Therapeutics worth $1.05M as of Q2 2026.
  • Barclays sold 18,531 Kyverna Therapeutics shares in Q2 2026, an estimated $165K.
  • Kyverna Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2764 holding.
  • Barclays first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Barclays's Kyverna Therapeutics position peaked at $1.55M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.